RNAGene Inc. announced that it has signed a Collaborative Research Agreement with PharmAbcine Inc. Under the agreement, both companies will collaborate to develop next-generation mRNA-based antibody therapeutics by utilizing the proprietary mRNA platform from RNAGENE. Unlike the existing antibody treatments, in which antibodies are artificially produced from external cell lines, mRNA-based therapies involve administration of mRNA in patients so that patients' own cells can produce the encoded therapeutic antibody.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
2,915 KRW | -8.91% | -.--% | -22.27% |
1st Jan change | Capi. | |
---|---|---|
-22.27% | 64.03M | |
+18.77% | 125B | |
+14.05% | 108B | |
-7.16% | 23.64B | |
+3.14% | 22.39B | |
-11.67% | 17.78B | |
-41.74% | 16.43B | |
-13.47% | 16.34B | |
+2.23% | 13.56B | |
+27.13% | 11.59B |
- Stock Market
- Equities
- A208340 Stock
- News PharmAbcine Inc.
- RNAGene Signs a Collaborative Research Agreement with PharmAbcine to Develop Novel Mrna Therapeutics